Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 111,300 shares, a decline of 23.5% from the June 30th total of 145,400 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.4% of the company’s stock are short sold.

Bio-Path Stock Performance

NASDAQ:BPTH remained flat at $1.77 during trading hours on Friday. 13,175 shares of the company were exchanged, compared to its average volume of 101,416. Bio-Path has a 12-month low of $1.59 and a 12-month high of $23.00. The business has a 50 day moving average of $2.07 and a 200-day moving average of $4.44.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($4.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.54) by ($0.34). On average, sell-side analysts forecast that Bio-Path will post -5.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Bio-Path in a research note on Thursday, May 2nd. They set a “sell” rating on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $20.00 price target on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.